Suggestions
Jeff Landau
Chief Business Officer at CytomX Therapeutics | Board Member Sunshine BIO and CLS
Jeff Landau is a seasoned biopharmaceutical executive with over 20 years of experience in corporate development, corporate strategy, and new product strategy and planning.13 He currently serves as the Senior Vice President, Head of Strategy and Chief Business Officer at CytomX Therapeutics.23
Professional Background
At CytomX Therapeutics, Landau is responsible for:
- Partnering
- License and acquisition
- Corporate strategy
- Pipeline and new product planning
- Alliance and project management1
Prior to joining CytomX, Landau held several notable positions:
- Senior Vice President of Corporate Development, Commercial, and New Product Strategy at Catalyst Biosciences, Inc.
- Corporate development and global product and pipeline strategy roles at Threshold Pharmaceuticals and Onyx Pharmaceuticals (acquired by Amgen)1
Education
Landau's educational background includes:
- M.B.A. from Stanford Graduate School of Business
- B.S. with honors in biochemistry/biotechnology from Virginia Polytechnic Institute1
Board Memberships
In addition to his role at CytomX, Landau serves on the Board of Directors for:
Jeff Landau's LinkedIn username is jeff-landau-9466ba3, as mentioned in the query.4
Highlights
Heading to Chicago tomorrow for #ASCO2024 and then directly to San Diego for #BIO2024.
Looking forward to seeing good friends and old colleagues, some great new data to benefit cancer patients and many meetings with both current and potential future collaborators for our industry leading Probody therapeutics masking platform and exciting clinical and research programs.
CytomX Therapeutics
#biotech #partnering
So happy for SCLC patients and congrats to Amgen for this landmark approval, the first T Cell Engager to be approved for a major solid tumor.
At CytomX Therapeutics we are proud to be at the forefront of TCE research unlocking previously undruggable targets for this powerful immunotherapy with our Probody platform as demonstrated by our recent positive interim Phase 1a results with CX-904 (Probody EGFRxCD3).
We are excited for the future and what we may bring to benefit patients with our four major Pharma TCE collaborations and over 10 active TCE programs Amgen Regeneron Astellas Pharma Bristol Myers Squibb
